BiotechTube

AB-101 + Rituximab + Interleukin-2 + Cyclophosphamide + Fludarabine + Bendamustine

Phase 1/2Active
0 watching 0 views this week💤 Quiet
33
Hype Score

Development Stage

✓
Pre-clinical
2
Phase 1
3
Phase 2
4
Phase 3
5
Approved
Indication / Disease

Non Hodgkin Lymphoma

Conditions

Non Hodgkin Lymphoma

Trial Timeline

Mar 29, 2021 → Dec 31, 2025

NCT ID
NCT04673617

About AB-101 + Rituximab + Interleukin-2 + Cyclophosphamide + Fludarabine + Bendamustine

AB-101 + Rituximab + Interleukin-2 + Cyclophosphamide + Fludarabine + Bendamustine is a phase 1/2 stage product being developed by Artiva Biotherapeutics for Non Hodgkin Lymphoma. The current trial status is active. This product is registered under clinical trial identifier NCT04673617. Target conditions include Non Hodgkin Lymphoma.

Hype Score Breakdown

Clinical
13
Activity
8
Company
2
Novelty
4
Community
3

Clinical Trials (1)

NCT IDPhaseStatus
NCT04673617Phase 1/2Active

Competing Products

20 competing products in Non Hodgkin Lymphoma

See all competitors
ProductCompanyStageHype Score
AFM13AffimedPhase 2
44
VIP152 + BTKiVincerx PharmaPhase 1
25
PLX3397Daiichi SankyoPhase 2
52
YM155 + RituximabAstellas PharmaPhase 2
52
TazemetostatEisaiPhase 2
52
ONTAKEisaiPhase 2
52
TazemetostatEisaiPhase 1
33
ME-401Kyowa KirinPhase 1
33
ME-401Kyowa KirinPhase 2
52
TirabrutinibOno PharmaceuticalPhase 1
33
ONO-7018Ono PharmaceuticalPhase 1
33
Nivolumab + Brentuximab vedotinOno PharmaceuticalPhase 3
77
ONO-7018 + ONO-7018Ono PharmaceuticalPhase 1
33
R-mabHDI and ABVD + ABVDEli LillyPhase 3
77
Prednisone + Vinblastine + Doxorubicin (Adriamycin) + GemcitabineEli LillyPhase 1/2
41
gemcitabineEli LillyPhase 2
52
gemcitabine + cisplatin + dexamethasoneEli LillyPhase 2
52
LY4152199 - IVEli LillyPhase 1
33
R-mabHD + ABVDEli LillyPhase 2
52
enzastaurin + placeboEli LillyPhase 3
77

Other Products from Artiva Biotherapeutics

Allogeneic NK CellsPhase 2
44
AFM13 + AB-101 + Cyclophosphamide + Fludarabine + Interleukin-2Phase 2
44
AB-201 + Cyclophosphamide + FludarabinePhase 1/2
33
GCC2005 + Cyclophosphamide + FludarabinePhase 1
25
AB-101 + Cyclophosphamide + Fludarabine + Rituximab + ObinutuzumabPhase 1
25